lutetium Lu 177-NeoB
Term · Oncology and biomedicine · MLC-T-ONC-014936
A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.
| Identifier | MLC-T-ONC-014936 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | lutetium 177-NeoB; 177Lu-NeoB; lutetium Lu 177 DOTA-NeoBOMB1; [177Lu]-NeoB |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014936",
"term": "lutetium Lu 177-NeoB",
"field": "Oncology and biomedicine",
"definition": "A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.",
"synonyms": [
"lutetium 177-NeoB",
"177Lu-NeoB",
"lutetium Lu 177 DOTA-NeoBOMB1",
"[177Lu]-NeoB"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-neob/"
}
Record 10,421 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.